SCHEMBL2408306

SCHEMBL2408306

CC(NC(=O)Nc1ccc(Cl)c(C(F)(F)F)c1)c1ccc(C(=O)NO)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 5/20 0.57
HDAC6 Q9UBN7 5/20 0.55
HDAC8 Q9BY41 3/20 0.53
HDAC1 Q13547 2/20 0.50
PDK1 Q15118 1/20 0.50
ABL1 P00519 2/20 0.49
BCR P11274 2/20 0.49
KIT P10721 1/20 0.48
BRAF P15056 1/20 0.48
FLT3 P36888 1/20 0.48
CASR P41180 1/20 0.48
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48
HDAC5 Q9UQL6 1/20 0.48
RAF1 P04049 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28898827 0.86 KDR (0.63) KDRPDK1CASRRAF1SLC6A3
SCHEMBL2407256 0.83 HDAC3 (0.54) HDAC6HDAC8HDAC3HDAC11TRPV1
SCHEMBL2407571 0.82 IDH1 (0.51) HDAC6HDAC8HDAC1LMNAMAPT
SCHEMBL2406864 0.82 KDR (0.56) KDRHDAC6HDAC8HDAC1PDK1
SCHEMBL1791236 0.80 KDR (0.54) KDRPDK1ABL1BCRBRAF
SCHEMBL2408579 0.80 SMN1; SMN2 (0.63) HDAC6HDAC8HDAC1HDAC3HDAC2
SCHEMBL12154419 0.80 KDR (0.75) KDRHDAC6HDAC8HDAC1PDK1
SCHEMBL2406106 0.79 MTOR (0.50) HDAC6HDAC8HDAC1HDAC3HDAC11
SCHEMBL2411765 0.79 TRPV1 (0.49) HDAC6HDAC8HDAC1HDAC3LMNA
SCHEMBL2405506 0.79 HSD17B10 (0.48) HDAC6HDAC8HDAC1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US disclosed
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US disclosed
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US disclosed
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-09-18 US disclosed
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-09-18 US disclosed
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-09-18 US disclosed
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC10, HDAC1 KDR 2256/4885HDAC6 1/4885HDAC8 15/4885
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC10, HDAC1 KDR 2256/4885HDAC6 1/4885HDAC8 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.